PharmAla Unveils Amended Preliminary Base Shelf Prospectus
TORONTO – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a pioneering biotechnology firm dedicated to the research and manufacturing of MDXX class molecules, recently announced the filing of an amended and restated preliminary short form base shelf prospectus. This initiative is designed to empower the Company with the necessary flexibility to seize financing opportunities and adapt to favorable market conditions during the effective period of the prospectus.
Flexibility in Financing Opportunities
The newly filed prospectus will be valid for a period of 25 months, maintaining its effectiveness until a final version is established. PharmAla aims to leverage this affordable source of financing whenever required. The detailed prospectus outlines the capacity for the Company to offer a variety of securities, including common shares, warrants, units, subscription receipts, and debt securities, with an aggregate offering price of up to C$30 million.
Strategic Offering Considerations
In an evolving market, the Company has judiciously adjusted the size of its offering based on the anticipated financial needs throughout the prospectus's effective span. This strategic adjustment signifies that PharmAla is refining its approach in alignment with market conditions and internal requirements.
Additionally, the prospectus allows for potential at-the-market distributions under applicable regulations, which could see the Company making sales through trading platforms like the Canadian Securities Exchange (CSE). So far, however, no formal agreements regarding such distributions have been established.
Current Position and Future Plans
PharmAla has expressed that it currently has no immediate plans to issue any securities under this prospectus. Should the need arise in the future, specifics regarding any offerings, including the usage of proceeds, will be elucidated in supplemental documentation provided to Canadian regulators.
Recent Developments in Debt Settlements
In a related announcement, PharmAla’s board has approved the resolution to settle $150,000 owed to creditors by issuing common shares at a price determined at the time of settlement. This move highlights the Company’s proactive management in addressing its financial obligations.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc., with a ticker under CSE: MDMA and OTC: MDXXF, is dedicated to advancing the MDXX class through the research and manufacture of closely related compounds, including its leading drug candidate, LaNeo™ MDMA. The company’s mission impacts the broader healthcare sector by addressing the existing global needs for clinical-grade MDMA during clinical trials while pursuing innovative drug development.
PharmAla uniquely positions itself as a leading provider of clinical-grade MDMA for patient care outside traditional trial settings. Its research and development team has made significant strides in areas such as ALA-002, signaling robust progress in its strategic journey. The Company's formation revolves around fostering positive regulatory relationships to propel success within the psychedelics market.
Contact Information
For further inquiries, reach out to:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is a base shelf prospectus?
A base shelf prospectus is a regulatory document that allows a company to offer securities to the public over a set period, providing flexibility in fundraising without needing to file a new prospectus each time.
How much is PharmAla looking to raise?
PharmAla's amended prospectus indicates it aims to raise up to C$30 million through various security offerings.
What kind of securities can PharmAla offer?
The Company can offer common shares, warrants, units, subscription receipts, and debt securities as per the new prospectus.
Are there immediate plans for new offerings?
Currently, PharmAla has no immediate plans to issue securities under the amended prospectus, but it remains open to future opportunities.
Who can I contact for more information about PharmAla?
Nicholas Kadysh, CEO, is the point of contact and can be reached via email at press@PharmAla.ca or by phone at 1-855-444-6362.
